Immunotherapy of multiple myeloma

Y. W. Huang, E. S. Vitetta

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

In 1994, an estimated 12,700 new cases of multiple myeloma (MM) will be diagnosed in the USA and 9,800 patients will die from this disease. At present, a cure for MM has not been achieved with any chemotherapeutic regimen. Therefore, it is important to develop novel therapeutic approaches to treat this fatal disease. This review focuses on new concepts in the immunotherapy of MM. Thus far, interferons and anti-human interleukin (IL)-6 monoclonal antibodies (MAbs) have been used to treat patients with this disease. Bone marrow transplantation using autologous marrow purged with MAbs and complement, with anti-myeloma immunotoxins (ITs), or MAb-magnetic bead conjugates has been reported. Adoptive cellular therapy, in vivo with anti- CD3 and IL-2, as well as transplantation of purified autologous CD34+ peripheral blood stem cells, is now being evaluated in clinical trials. Antihuman IL-6 receptor (IL-6R) and anti-CD54 (ICAM-1) MAbs have shown promising results in the therapy of human myeloma cell lines in SCID mice, while an IL-6 antagonist protein, anti-gp130 MAbs, recombinant soluble gp130, anti-B7, anti-HLA-DR, and recombinant soluble CD16 also inhibit the growth of myeloma cell lines in vitro. These experimental therapeutic modalities hold promise for use in humans and may also provide further insights into the pathogenesis of MM.

Original languageEnglish (US)
Pages (from-to)123-134
Number of pages12
JournalStem Cells
Volume13
Issue number2
StatePublished - 1995

Fingerprint

Multiple Myeloma
Immunotherapy
Monoclonal Antibodies
Cytokine Receptor gp130
Interleukin-6 Receptors
Immunotoxins
Cell Line
SCID Mice
Autologous Transplantation
HLA-DR Antigens
Intercellular Adhesion Molecule-1
Therapeutics
Bone Marrow Transplantation
Interferons
Interleukin-2
Interleukin-6
Bone Marrow
Clinical Trials
Growth
Proteins

Keywords

  • Antibodies
  • Bone marrow
  • Immunotherapy
  • Interleukins
  • Multiple myeloma

ASJC Scopus subject areas

  • Cell Biology

Cite this

Huang, Y. W., & Vitetta, E. S. (1995). Immunotherapy of multiple myeloma. Stem Cells, 13(2), 123-134.

Immunotherapy of multiple myeloma. / Huang, Y. W.; Vitetta, E. S.

In: Stem Cells, Vol. 13, No. 2, 1995, p. 123-134.

Research output: Contribution to journalArticle

Huang, YW & Vitetta, ES 1995, 'Immunotherapy of multiple myeloma', Stem Cells, vol. 13, no. 2, pp. 123-134.
Huang, Y. W. ; Vitetta, E. S. / Immunotherapy of multiple myeloma. In: Stem Cells. 1995 ; Vol. 13, No. 2. pp. 123-134.
@article{822ee57abd814d02bd15863fdde81dba,
title = "Immunotherapy of multiple myeloma",
abstract = "In 1994, an estimated 12,700 new cases of multiple myeloma (MM) will be diagnosed in the USA and 9,800 patients will die from this disease. At present, a cure for MM has not been achieved with any chemotherapeutic regimen. Therefore, it is important to develop novel therapeutic approaches to treat this fatal disease. This review focuses on new concepts in the immunotherapy of MM. Thus far, interferons and anti-human interleukin (IL)-6 monoclonal antibodies (MAbs) have been used to treat patients with this disease. Bone marrow transplantation using autologous marrow purged with MAbs and complement, with anti-myeloma immunotoxins (ITs), or MAb-magnetic bead conjugates has been reported. Adoptive cellular therapy, in vivo with anti- CD3 and IL-2, as well as transplantation of purified autologous CD34+ peripheral blood stem cells, is now being evaluated in clinical trials. Antihuman IL-6 receptor (IL-6R) and anti-CD54 (ICAM-1) MAbs have shown promising results in the therapy of human myeloma cell lines in SCID mice, while an IL-6 antagonist protein, anti-gp130 MAbs, recombinant soluble gp130, anti-B7, anti-HLA-DR, and recombinant soluble CD16 also inhibit the growth of myeloma cell lines in vitro. These experimental therapeutic modalities hold promise for use in humans and may also provide further insights into the pathogenesis of MM.",
keywords = "Antibodies, Bone marrow, Immunotherapy, Interleukins, Multiple myeloma",
author = "Huang, {Y. W.} and Vitetta, {E. S.}",
year = "1995",
language = "English (US)",
volume = "13",
pages = "123--134",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "2",

}

TY - JOUR

T1 - Immunotherapy of multiple myeloma

AU - Huang, Y. W.

AU - Vitetta, E. S.

PY - 1995

Y1 - 1995

N2 - In 1994, an estimated 12,700 new cases of multiple myeloma (MM) will be diagnosed in the USA and 9,800 patients will die from this disease. At present, a cure for MM has not been achieved with any chemotherapeutic regimen. Therefore, it is important to develop novel therapeutic approaches to treat this fatal disease. This review focuses on new concepts in the immunotherapy of MM. Thus far, interferons and anti-human interleukin (IL)-6 monoclonal antibodies (MAbs) have been used to treat patients with this disease. Bone marrow transplantation using autologous marrow purged with MAbs and complement, with anti-myeloma immunotoxins (ITs), or MAb-magnetic bead conjugates has been reported. Adoptive cellular therapy, in vivo with anti- CD3 and IL-2, as well as transplantation of purified autologous CD34+ peripheral blood stem cells, is now being evaluated in clinical trials. Antihuman IL-6 receptor (IL-6R) and anti-CD54 (ICAM-1) MAbs have shown promising results in the therapy of human myeloma cell lines in SCID mice, while an IL-6 antagonist protein, anti-gp130 MAbs, recombinant soluble gp130, anti-B7, anti-HLA-DR, and recombinant soluble CD16 also inhibit the growth of myeloma cell lines in vitro. These experimental therapeutic modalities hold promise for use in humans and may also provide further insights into the pathogenesis of MM.

AB - In 1994, an estimated 12,700 new cases of multiple myeloma (MM) will be diagnosed in the USA and 9,800 patients will die from this disease. At present, a cure for MM has not been achieved with any chemotherapeutic regimen. Therefore, it is important to develop novel therapeutic approaches to treat this fatal disease. This review focuses on new concepts in the immunotherapy of MM. Thus far, interferons and anti-human interleukin (IL)-6 monoclonal antibodies (MAbs) have been used to treat patients with this disease. Bone marrow transplantation using autologous marrow purged with MAbs and complement, with anti-myeloma immunotoxins (ITs), or MAb-magnetic bead conjugates has been reported. Adoptive cellular therapy, in vivo with anti- CD3 and IL-2, as well as transplantation of purified autologous CD34+ peripheral blood stem cells, is now being evaluated in clinical trials. Antihuman IL-6 receptor (IL-6R) and anti-CD54 (ICAM-1) MAbs have shown promising results in the therapy of human myeloma cell lines in SCID mice, while an IL-6 antagonist protein, anti-gp130 MAbs, recombinant soluble gp130, anti-B7, anti-HLA-DR, and recombinant soluble CD16 also inhibit the growth of myeloma cell lines in vitro. These experimental therapeutic modalities hold promise for use in humans and may also provide further insights into the pathogenesis of MM.

KW - Antibodies

KW - Bone marrow

KW - Immunotherapy

KW - Interleukins

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=0028954279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028954279&partnerID=8YFLogxK

M3 - Article

C2 - 7540468

AN - SCOPUS:0028954279

VL - 13

SP - 123

EP - 134

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 2

ER -